Clinical Trial Update: An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of RNActive cancer vaccine in high risk and intermediate risk prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RNActive® Cancer Vaccine (RNActive cancer vaccine)

Snippet

Sponsor: CureVac | Conditions: Prostate Carcinoma | Phase 2 | Status: TERMINATED